All In Biotech

NDA 208694 · Harrow Eye

Zerviate

Cetirizine Hydrochloride · Ophthalmic · Histamine-1 Receptor Antagonist

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

May 30, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

43,309

34,381 serious, 5,083 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 3, 2026.

ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis. ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis. ( 1 )

Mechanism: ZERVIATE ® , an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZERVIATE · CETIRIZINE HYDROCHLORIDE EQ 0.24% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,853
  • drug ineffective5,324
  • pain5,158
  • rash5,124
  • off label use4,634
  • dyspnoea4,628
  • pruritus4,543
  • arthralgia4,078
  • pyrexia3,959
  • hypersensitivity3,788
  • headache3,709
  • nausea3,701

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20059
200634
20071
200814
2009149
201051
2011139
2012575
2013732
20141,189
20151,657
20162,030
20172,063
20182,874
20193,253
20203,691
20214,135
20223,599
20233,845
20244,820
20255,075
20263,370

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zerviate (Cetirizine HCl)

2024 spending

$3.9M

Beneficiaries

3,309

10,118 claims

Per beneficiary

$1,164

$7.31 per unit

View as table
YearSpending
2020$1,644,591
2021$8,220,413
2022$4,350,525
2023$8,592,881
2024$3,852,825

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.